Citizens JMP analyst Constantine Davides lowered the firm’s price target on Option Care Health (OPCH) to $36 from $38 and keeps an Outperform rating on the shares. Option Care’s Q3 revenue and gross profit topped the firm’s estimates, and Citizens tells investors in a research note that deployment toward Option’s own stock is a prudent use of capital. The firm remains constructive on Option Care given the company’s leading scale and market share, comprehensive therapeutic portfolio, differentiated platform, optionality from potential capital deployment and its meaningful discount to multiples paid in recent infusion transactions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health Reports Strong Q3 2025 Results
- Option Care Health: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Option Care Health reports Q3 adjusted EPS 45c, consensus 43c
- Option Care Health sees FY25 adjusted EPS $1.68-$1.72, consensus $1.71
- Option Care Health Inc (OPCH) Q3 Earnings Cheat Sheet